SK Bioscience rolled out the first batch of Nuvaxovid, Novavax’s synthetic antigen-based COVID-19 vaccine, the company said Wednesday.

On top of the 840,000 doses that were rolled out on Wednesday, SK Bioscience said it plans to supply a total of 2 million doses by the end of this month. The shipment follows the Ministry of Food and Drug Safety’s approval of the vaccine last month.